Antifibrotic therapy of idiopathic pulmonary fibrosis: efficiency / safety ratio
Idiopathic pulmonary fibrosis (IPF) is the most common form of idiopathic interstitial pneumonia that is characterized by a steadily progressive course and poor prognosis. The worsening pulmonary fibrosis resulting in honeycomb lungs accounts for the deterioration of clinical symptoms and functional...
Main Authors: | S. N. Avdeev, N. V. Trushenko |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2018-10-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/2682 |
Similar Items
-
Antifibrotic activities of pirfenidone in animal models
by: L. Pan, et al.
Published: (2011-06-01) -
Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis
by: Ulrich Costabel, et al.
Published: (2019-03-01) -
Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study
by: Yuzo Suzuki, et al.
Published: (2021-07-01) -
Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis
by: Keishi Sugino, et al.
Published: (2021-07-01) -
Patients’ and Healthcare Professionals’ Experiences of Idiopathic Pulmonary Fibrosis Treatment with the Pirfenidone 801 mg Tablet Formulation: A Multinational Survey
by: Lisa H. Lancaster, et al.
Published: (2020-03-01)